Opening book details…
Can I read Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study on EtoBox?
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study by Sergey N. Avdeev; Natalia V. Trushenko; Natalia A. Tsareva; Andrey I. Yaroshetskiy; Zamira M. Merzhoeva; Galia S. Nuralieva; Galina V. Nekludova; Svetlana Yu. Chikina; Tatiana Yu. Gneusheva; Olga A. Suvorova; Anna E. Shmidt is a Immunology and Microbiology article available to read on EtoBox.
What is Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study about?
Background: One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome. Objective: To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. Study design. In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously. Results: 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups. ## Conclusion: In hospitalized patients with severe CO
Who reads Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study?
It is typically read by researchers, students, and practitioners in Immunology and Microbiology.
- Author
- Sergey N. Avdeev; Natalia V. Trushenko; Natalia A. Tsareva; Andrey I. Yaroshetskiy; Zamira M. Merzhoeva; Galia S. Nuralieva; Galina V. Nekludova; Svetlana Yu. Chikina; Tatiana Yu. Gneusheva; Olga A. Suvorova; Anna E. Shmidt
- Publisher
- Elsevier BV
- Published
- 2021
- Language
- EN
- Field
- Immunology and Microbiology (Life Sciences)